<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438451</url>
  </required_header>
  <id_info>
    <org_study_id>STEPONE05</org_study_id>
    <secondary_id>ISRCTN: 94839639</secondary_id>
    <secondary_id>EudraCT Number:2005-003324-19</secondary_id>
    <nct_id>NCT00438451</nct_id>
  </id_info>
  <brief_title>Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs</brief_title>
  <acronym>STEP-ONE</acronym>
  <official_title>A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trial patients with newly diagnosed focal epilepsy aged 60 years or older
      receive three different antiepileptic drugs in a double-blind, randomized design over a
      period of 58 weeks. All drugs are licensed for the treatment of epilepsy. The primary
      endpoint of this study will be retention rate at 58-weeks, since it reflects both efficacy
      and tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication: Focal Epilepsy Objectives: To evaluate the tolerability and efficacy of
      levetiracetam (LEV) in newly diagnosed elderly patients (aged 60 yrs or above) with focal
      epilepsy compared to lamotrigine (LTG) or carbamazepine slow release (CBZ).

      Primary Outcome: The primary outcome will be the 58-week retention rate measured by the
      number of drop outs due to adverse events or seizures from day 1 of treatment.

      Secondary Outcome: Proportion of patients remaining seizure-free at week 30 (Visit 4);
      proportion of patients remaining seizure free at week 58 (Visit 6); the time (in days) to
      first break-through seizure (from day 1 of treatment); the absolute seizure frequency during
      the maintenance (over 52 weeks) phase; proportion of seizure-free days during the maintenance
      phase for subjects who enter the maintenance phase; the frequency of adverse events (from day
      1 of treatment); QOLIE-31 results at V6; Portland Neurotoxicity scale at V6; results of
      cognitive testing (EpiTrack© by UCB).

      Trial Design: This is a randomized, double-blind, multicenter Phase IV study using a parallel
      group design with three treatment groups. The study will consist of a 6-week titration-phase
      and a 52-week maintenance phase. Patients who successfully complete the trial (final visit,
      V6) will be unblinded and offered either to continue on their current drug or be changed to
      an alternative antiepileptic drug (AED) treatment of choice.

      Population: Patients aged 60 years or above with new onset focal epilepsy i.e. either at
      least one epileptic seizure in the last 6 months and focal epileptiform discharges on EEG or
      a relevant lesion on CT/MRI or a total of 2 epileptic seizures, one of which occurring in the
      last 6 months prior inclusion. Patients with acute (&lt; 2 weeks) symptomatic epileptic seizures
      due to acute brain abnormalities (i.e. haemorrhage or cerebral infarct), or contraindications
      against any of the drugs in trial will be excluded.

      Sample Size: 360 patients to be included, 120 patients per treatment arm. Investigational
      Medicinal Product(s): Levetiracetam, lamotrigine, carbamazepine-slow release Trial Duration
      and Dates: Duration of treatment: 6 weeks titration phase, 52 weeks maintenance phase.

      Follow up: At the end of trial subjects will be unblinded and may choose to continue on the
      medication or taper the trial medication and be treated with an alternative drug at the
      investigators discretion. The patient will receive a dosing schedule and a referral letter
      for his/her physician.

      Duration of trial: approximately 2 years. Start of recruitment: January 2007 Projected number
      of centres: 75 Number of countries: 3 (Germany, Switzerland, Austria).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment</measure>
    <time_frame>58 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Drop Out</measure>
    <time_frame>58 weeks</time_frame>
    <description>number of days between randomization and premature discontinuation of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)</measure>
    <time_frame>Week 30</time_frame>
    <description>Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)</measure>
    <time_frame>week 58</time_frame>
    <description>Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)</measure>
    <time_frame>over the whole duration of 58 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)</measure>
    <time_frame>over 52 weeks</time_frame>
    <description>Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.
The absolute seizure frequency during the maintenance phase was defined as the sum of those entries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOLIE-31 (Quality Of Life In Epilepsy) Results at V6</measure>
    <time_frame>58 weeks, final visit</time_frame>
    <description>The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portland Neurotoxicity Scale (PNS) at V6</measure>
    <time_frame>at week 58</time_frame>
    <description>The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.
Lower values indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6</measure>
    <time_frame>week 58</time_frame>
    <description>EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6</measure>
    <time_frame>58 weeks</time_frame>
    <description>Evaluation of current testing at V6:
≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;
≤25 score points: Impaired</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)</measure>
    <time_frame>week 58</time_frame>
    <description>Evaluation of Changes
Changes in the EpiTrack® Score were categorized as follows:
≥5 score points: Improved;
-3 to 4 score points: Unchanged;
≤-4 score points: Worsened</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levetiracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbamazepine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbamazepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamotrigine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.</description>
    <arm_group_label>Levetiracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.</description>
    <arm_group_label>Carbamazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.</description>
    <arm_group_label>Lamotrigine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 60 yrs or above.

          -  New onset focal epilepsy i.e. either at least one epileptic seizure in the last 6
             months and focal epileptiform discharges on EEG or a relevant lesion on CT/MRI or at
             least 2 epileptic seizures, one of which occurring in the last 6 months prior
             inclusion.

          -  No previous AED treatment, except for a period not longer than 4 weeks prior to
             inclusion (V0).

          -  Ability of subject to understand verbal and written instructions, to comply with all
             study requirements, and to comprehend character and individual consequences of the
             clinical trial.

          -  Written informed consent before enrolment in the trial.

        Exclusion Criteria:

          -  Acute symptomatic epileptic seizures occurring acutely within a 2 week period after
             the onset of an acute illness such as cerebral haemorrhage, cerebral infarct, rapid
             progressive malignancy or other acute brain abnormalities (i.e. encephalitis, hypoxic
             brain damage, trauma, metabolic derangement, following brain surgery).

          -  Dementia (as defined by history)

          -  Renal insufficiency as defined by GFR &lt; 50 mL/min.

          -  Increased liver enzymes (GOT, GPT, gGT) or increased bilirubin ≥ 2-fold the upper
             limit of normal (ULN).

          -  Pre-treatment with valproic acid within the four weeks prior inclusion (V0).

          -  Contraindication against or history of hypersensitivity to any of the investigational
             medicinal products or to any drug with similar chemical structure or to any excipient
             present in the pharmaceutical form of the investigational medicinal products.

          -  Participation in other clinical trials and observation period of competing trials
             within the last 2 months, respectively.

          -  History of drug or alcohol abuse within the last 2 years.

          -  Medical condition which interferes with the participation in the trial according to
             the opinion of the investigator.

          -  Patients with life expectancy &lt; 1 year due to malignant disease

          -  Psychiatric morbidity requiring legal guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad J Werhahn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johannes Gutenberg University, Department od Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Günter Kraemer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Swiss Epilepy Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugen Trinka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Salzburg, Department of Neurology, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University of Mainz Medical Centre</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks W, Felicetta J, Tomyanovich ML; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005 Jun 14;64(11):1868-73.</citation>
    <PMID>15955935</PMID>
  </reference>
  <reference>
    <citation>Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, Sauermann W, Murray G, Garofalo EA; Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002 Sep;43(9):993-1000.</citation>
    <PMID>12199724</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <results_first_submitted>September 24, 2012</results_first_submitted>
  <results_first_submitted_qc>January 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2013</results_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Konrad J. Werhahn</investigator_full_name>
    <investigator_title>Prof of Neurology, Head Section on Epilepsy</investigator_title>
  </responsible_party>
  <keyword>elderly</keyword>
  <keyword>focal epilepsy</keyword>
  <keyword>anticonvulsive</keyword>
  <keyword>treatment</keyword>
  <keyword>levetiracetam</keyword>
  <keyword>lamotrigine</keyword>
  <keyword>carbamazepine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>43 study centres in three countries participated in this study (31 in Germany, 5 in Austria, 7 in Switzerland). The number of patients recruited in each country (242 Germany, 55 Austria, 29 Switzerland) and per centre (range from 1 to 53) was heterogeneous.
Therefore, centre effects were explored by pooling the centres with less than 20 subjects.</recruitment_details>
      <pre_assignment_details>In total, 361 patients were randomized. 359 patients were analysed ITT (patient 0213 did not suffer from epilepsy, patient 3604 should not have been asked for informed consent, because of his legal guardianship).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levetiracetam</title>
          <description>Levetiracetam 250mg: capsules, each containing one Levetiracetam 250mg film-coated tablet.
During titration phase, subjects received 1 capsule in the evening in the first 14 days, 2 capsules (1 in the morning and 1 in the evening) in week 3 and 4, 3 capsules in week 5 (1 in the morning and 2 in the evening) and 4 capsules from week 6 onwards (2 in the morning and 2 in the evening). During maintenance phase, dose adjustments could be made according to tolerability and seizure control in steps of 1 capsule per week. Dosages between 2 to 12 capsules per day were allowed.</description>
        </group>
        <group group_id="P2">
          <title>Carbamazepine</title>
          <description>Carbamazepine 100mg: capsules, each containing half of one Carbamazepine 200mg slow release tablet.
During titration phase, subjects received 1 capsule in the evening in the first 14 days, 2 capsules (1 in the morning and 1 in the evening) in week 3 and 4, 3 capsules in week 5 (1 in the morning and 2 in the evening) and 4 capsules from week 6 onwards (2 in the morning and 2 in the evening). During maintenance phase, dose adjustments could be made according to tolerability and seizure control in steps of 1 capsule per week. Dosages between 2 to 12 capsules per day were allowed.</description>
        </group>
        <group group_id="P3">
          <title>Lamotrigine</title>
          <description>Lamotrigine 25mg: capsules, each containing one Lamotrigine 25mg tablet. During titration phase, subjects received 1 capsule in the evening in the first 14 days, 2 capsules (1 in the morning and 1 in the evening) in week 3 and 4, 3 capsules in week 5 (1 in the morning and 2 in the evening) and 4 capsules from week 6 onwards (2 in the morning and 2 in the evening). During maintenance phase, dose adjustments could be made according to tolerability and seizure control in steps of 1 capsule per week. Dosages between 2 to 12 capsules per day were allowed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Maintenance Phase (Week 7-58)</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levetiracetam</title>
          <description>Levetiracetam 250mg</description>
        </group>
        <group group_id="B2">
          <title>Carbamazepine</title>
          <description>Carbamazepine 100mg</description>
        </group>
        <group group_id="B3">
          <title>Lamotrigine</title>
          <description>Lamotrigine 25mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="117"/>
            <count group_id="B4" value="359"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age is shown for ITT population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="7.49"/>
                    <measurement group_id="B2" value="71.7" spread="6.66"/>
                    <measurement group_id="B3" value="70.7" spread="7.43"/>
                    <measurement group_id="B4" value="71.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Race is shown for ITT population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Region of enrollment is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epilepsy history - number of seizures</title>
          <description>is shown for ITT population</description>
          <units>number of seizures</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="9.85"/>
                    <measurement group_id="B2" value="4.8" spread="10.78"/>
                    <measurement group_id="B3" value="2.7" spread="3.14"/>
                    <measurement group_id="B4" value="3.75" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epilepsy history - Aura</title>
          <description>is shown for ITT population &quot;NA&quot; refer to the fact that the epilepsy history - Aura is unknown</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epilepsy history - Autonomic seizure</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epilepsy history - Dialeptic seizure</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epilepsy history - Motor seizure</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epileptic history - Special seizure</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EEG (electroencephalogram) pathological</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRT (Magnetic Resonance Tomograhy) pathological</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CCT (Cranial Computed Tomography) pathological</title>
          <description>is shown for ITT population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment</title>
        <time_frame>58 weeks</time_frame>
        <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment</title>
          <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
          <units>proportion of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.53" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.46" lower_limit="0.37" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.47" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1536</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3615</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0478</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0578</p_value>
            <method>Regression, Logistic</method>
            <method_desc>adjusted for treatment (p=0.0578), country (p=0.4649), pooled sites (p=0.4420) and number of concurrent diseases (p=0.0192)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.838</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.092</ci_lower_limit>
            <ci_upper_limit>3.093</ci_upper_limit>
            <estimate_desc>Odds ratio given here is for comparison &quot;LEV vs CBZ&quot;: OR=1.838 KI=(1.092-3.093) &quot;LEV vs LTG&quot;: OR=1.169 KI=(0.689-1.984) &quot;CBZ vs LTG&quot;: OR=0.636 KI=(0.377-1.073) &quot;Number of concurrent diseases&quot;: OR=0.921 KI=(0.859-0.987)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Drop Out</title>
        <description>number of days between randomization and premature discontinuation of the study</description>
        <time_frame>58 weeks</time_frame>
        <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Drop Out</title>
          <description>number of days between randomization and premature discontinuation of the study</description>
          <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">less than 50% of patients dropped out</measurement>
                    <measurement group_id="O2" value="265" lower_limit="119">not enough patients dropped out</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="270">less than 50% of patients dropped out</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0596</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)</title>
        <description>Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30.</description>
        <time_frame>Week 30</time_frame>
        <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)</title>
          <description>Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30.</description>
          <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2517</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)</title>
        <description>Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58.</description>
        <time_frame>week 58</time_frame>
        <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)</title>
          <description>Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58.</description>
          <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3303</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)</title>
        <time_frame>over the whole duration of 58 weeks</time_frame>
        <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)</title>
          <population>ITT population:
All randomized patients were included in the Intention-to-Treat (ITT) population except patients that were not evaluable for efficacy e.g. patients without epilepsy or patients not able to comply with the study requirements.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">could not be estimated since there were less than 50% events</measurement>
                    <measurement group_id="O2" value="NA">could not be estimated since there were less than 50% events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="308">could not be estimated since there were less than 50% events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5022</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)</title>
        <description>Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.
The absolute seizure frequency during the maintenance phase was defined as the sum of those entries.</description>
        <time_frame>over 52 weeks</time_frame>
        <population>Completer population:
The completer population comprises all patients still being in the study at week 58 (This definition deviates minimally from the protocol. It could not be assessed from the CRF data, if patients were on treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)</title>
          <description>Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.
The absolute seizure frequency during the maintenance phase was defined as the sum of those entries.</description>
          <population>Completer population:
The completer population comprises all patients still being in the study at week 58 (This definition deviates minimally from the protocol. It could not be assessed from the CRF data, if patients were on treatment).</population>
          <units>number of seizures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase</title>
        <time_frame>52 weeks</time_frame>
        <population>Patients of ITT population who reached the maintenance phase</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase</title>
          <population>Patients of ITT population who reached the maintenance phase</population>
          <units>proportion of seizure-free days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99"/>
                    <measurement group_id="O2" value="0.99"/>
                    <measurement group_id="O3" value="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QOLIE-31 (Quality Of Life In Epilepsy) Results at V6</title>
        <description>The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100.</description>
        <time_frame>58 weeks, final visit</time_frame>
        <population>Patients of ITT population who filled out QOLIE-31 at V6</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>QOLIE-31 (Quality Of Life In Epilepsy) Results at V6</title>
          <description>The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100.</description>
          <population>Patients of ITT population who filled out QOLIE-31 at V6</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seizure worry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.1" spread="19.89" lower_limit="25" upper_limit="100"/>
                    <measurement group_id="O2" value="75.4" spread="26.87" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="75.0" spread="26.26" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall quality of life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="21.76" lower_limit="10" upper_limit="100"/>
                    <measurement group_id="O2" value="65.0" spread="20.65" lower_limit="5" upper_limit="100"/>
                    <measurement group_id="O3" value="67.1" spread="20.96" lower_limit="10" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" spread="19.42" lower_limit="16" upper_limit="100"/>
                    <measurement group_id="O2" value="69.8" spread="18.76" lower_limit="20" upper_limit="100"/>
                    <measurement group_id="O3" value="67.4" spread="20.25" lower_limit="16" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="21.03" lower_limit="15" upper_limit="100"/>
                    <measurement group_id="O2" value="54.5" spread="21.33" lower_limit="5" upper_limit="95"/>
                    <measurement group_id="O3" value="59.8" spread="22.07" lower_limit="10" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="19.48" lower_limit="10" upper_limit="100"/>
                    <measurement group_id="O2" value="68.9" spread="20.96" lower_limit="18" upper_limit="100"/>
                    <measurement group_id="O3" value="68.0" spread="21.11" lower_limit="10" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medication effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="26.78" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="70.6" spread="28.21" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="72.6" spread="30.34" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="19.23" lower_limit="25" upper_limit="100"/>
                    <measurement group_id="O2" value="76.3" spread="25.49" lower_limit="5" upper_limit="100"/>
                    <measurement group_id="O3" value="76.7" spread="24.28" lower_limit="5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="15.89" lower_limit="26" upper_limit="100"/>
                    <measurement group_id="O2" value="68.9" spread="17.80" lower_limit="30" upper_limit="96"/>
                    <measurement group_id="O3" value="69.1" spread="17.12" lower_limit="17" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" spread="19.28" lower_limit="20" upper_limit="100"/>
                    <measurement group_id="O2" value="65.7" spread="21.21" lower_limit="10" upper_limit="100"/>
                    <measurement group_id="O3" value="67.5" spread="19.84" lower_limit="20" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Portland Neurotoxicity Scale (PNS) at V6</title>
        <description>The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.
Lower values indicate better quality of life.</description>
        <time_frame>at week 58</time_frame>
        <population>Patients of ITT population who filled out PNS at V6</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Portland Neurotoxicity Scale (PNS) at V6</title>
          <description>The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.
Lower values indicate better quality of life.</description>
          <population>Patients of ITT population who filled out PNS at V6</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive toxicity subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="12.52" lower_limit="10" upper_limit="79"/>
                    <measurement group_id="O2" value="27.3" spread="15.71" lower_limit="10" upper_limit="82"/>
                    <measurement group_id="O3" value="23.7" spread="11.44" lower_limit="10" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somatomotor subscore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="5.53" lower_limit="5" upper_limit="28"/>
                    <measurement group_id="O2" value="11.4" spread="6.96" lower_limit="5" upper_limit="35"/>
                    <measurement group_id="O3" value="10.8" spread="5.42" lower_limit="5" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="16.81" lower_limit="15" upper_limit="107"/>
                    <measurement group_id="O2" value="38.7" spread="21.73" lower_limit="15" upper_limit="110"/>
                    <measurement group_id="O3" value="34.5" spread="15.67" lower_limit="15" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6</title>
        <description>EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45.</description>
        <time_frame>week 58</time_frame>
        <population>Patients of ITT population who had data at V6</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6</title>
          <description>EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45.</description>
          <population>Patients of ITT population who had data at V6</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="7.22" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O2" value="26.0" spread="7.05" lower_limit="8" upper_limit="39"/>
                    <measurement group_id="O3" value="25.4" spread="6.82" lower_limit="7" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6</title>
        <description>Evaluation of current testing at V6:
≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;
≤25 score points: Impaired</description>
        <time_frame>58 weeks</time_frame>
        <population>Patients of ITT population with data at V6</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6</title>
          <description>Evaluation of current testing at V6:
≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;
≤25 score points: Impaired</description>
          <population>Patients of ITT population with data at V6</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without pathological findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Borderline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)</title>
        <description>Evaluation of Changes
Changes in the EpiTrack® Score were categorized as follows:
≥5 score points: Improved;
-3 to 4 score points: Unchanged;
≤-4 score points: Worsened</description>
        <time_frame>week 58</time_frame>
        <population>Patients of ITT population with data at V6 and V0</population>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam</title>
            <description>Levetiracetam 250mg</description>
          </group>
          <group group_id="O2">
            <title>Carbamazepine</title>
            <description>Carbamazepine 100mg</description>
          </group>
          <group group_id="O3">
            <title>Lamotrigine</title>
            <description>Lamotrigine 25mg</description>
          </group>
        </group_list>
        <measure>
          <title>Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)</title>
          <description>Evaluation of Changes
Changes in the EpiTrack® Score were categorized as follows:
≥5 score points: Improved;
-3 to 4 score points: Unchanged;
≤-4 score points: Worsened</description>
          <population>Patients of ITT population with data at V6 and V0</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from day 1 of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levetiracetam</title>
          <description>Levetiracetam 250mg</description>
        </group>
        <group group_id="E2">
          <title>Carbamazepine</title>
          <description>Carbamazepine 100mg</description>
        </group>
        <group group_id="E3">
          <title>Lamotrigine</title>
          <description>Lamotrigine 25mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute mycardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Helicobacter test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnestic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Partial seizures with secondary generalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Suicidal behavior</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bursa removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningioma surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radiotherapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="48" subjects_affected="31" subjects_at_risk="122"/>
                <counts group_id="E2" events="51" subjects_affected="46" subjects_at_risk="121"/>
                <counts group_id="E3" events="29" subjects_affected="23" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="122"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E3" events="23" subjects_affected="11" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="52" subjects_affected="35" subjects_at_risk="122"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="121"/>
                <counts group_id="E3" events="44" subjects_affected="36" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="35" subjects_affected="19" subjects_at_risk="122"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E3" events="22" subjects_affected="14" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="31" subjects_at_risk="122"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="121"/>
                <counts group_id="E3" events="44" subjects_affected="29" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="19" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>This study was supported (as investigator-initated trial) by an educational grant from UCB GmbH, Germany. A disclosure restriction applies on the PI in that UCB can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted. As of Jan-01-2012 the study chair is an employee to UCB Biosciences GmbH working as Medical Director in the Therapeutic Area CNS within Global Projects and Development.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>C. Ruckes</name_or_title>
      <organization>Interdisciplinary Center for Clinical Trials (IZKS Mainz)</organization>
      <phone>+49 (0) 6131 17 ext 9919</phone>
      <email>ruckes@izks-mainz.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

